Home>Topics>Companies>Barr Pharmaceuticals

Barr Pharmaceuticals BRL

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. New Morningstar Analyst Report for Actavis PLC

      Stock Reports

      Wed, 12 Mar 2014

      long haul. Paul Bisaro has been president and CEO of Actavis (formerly Watson) since 2007. Bisaro came from Barr Pharmaceuticals , where he worked since 1992, most recently as president and COO. Some of the directors, including chairman

    2. Stockton is Bankrupt: Now What?

      Headlines

      Thu, 11 Apr 2013

      raises questions about the broader implications of the practice for the generic drug industry. Analyst Report: Barr Pharmaceuticals BRL Analyst Report: Dr. Reddy Laboratories RDY Analyst Report: Merck Analyst Report: Mylan Technologies MYL

    3. What Maslow and Rand Would Tell Investors Today

      Headlines

      Tue, 2 Apr 2013

      We're placing Barr Pharmaceuticals BRL under review while we evaluate the company's decision, announced Tuesday, to acquire Pliva. Barr is paying $2.2 billion

    4. New Morningstar Analyst Report - Watson Pharmaceuticals Inc.

      Stock Reports

      Mon, 17 Sep 2012

      on capital over the long haul. Paul Bisaro has been president and CEO of Watson since 2007. Bisaro came from Barr Pharmaceuticals , where he worked since 1992, most recently as president and COO. Some of the directors, including Andrew

    5. Teva Acquires Ratiopharm

      Headlines

      Thu, 12 Aug 2010

      186 million (a total value of approximately $4.95 billion). Teva’s last major acquisition was that of Barr Pharmaceuticals , a US-based multinational generic pharmaceutical company with operations mainly in the US and Europe. This acquisition

    6. New Morningstar Analyst Report - Celgene

      Stock Reports

      Wed, 20 Jan 2010

      lead to pricing pressure down the road.Teva-owned Barr Pharmaceuticals has filed for approval of a generic version of Thalomid ..... competitive pressures are also mounting. Teva TEVA-owned Barr Pharmaceuticals is attempting to launch a generic version of Thalomid

    7. Teva May Postpone Barr Acquisition

      Commentary

      Thu, 9 Oct 2008

      We're maintaining our fair value estimate for Barr Pharmaceuticals BRL at Teva's TEVA negotiated acquisition price of $67 per share despite a breakdown in the commercial paper market that could make

    8. Par under Review

      Commentary

      Fri, 8 Aug 2008

      in these areas take the steam out of any near-term growth. It's also a sign of the company's inability to compete effectively against the larger, more efficient, U.S. generic competitors like Mylan MYL, Barr BRL , and Teva TEVA.

    9. Strong 2Q for Mylan

      Commentary

      Wed, 6 Aug 2008

      generic oral contraceptives in 2010; this pact would shake up the longstanding generic oral contraceptives duopoly between Barr BRL and Watson WPI. The pending acquisition of Barr by Teva TEVA announced last quarter consolidates two major global competitors

    10. Teva Agrees to Buy Barr

      Commentary

      Fri, 18 Jul 2008

      Teva Pharmaceutical TEVA agreed Friday to buy Barr Pharmaceuticals BRL for $67 per share. We're bringing Barr's fair value estimate in line with the purchase price, as we believe the deal will

    « Prev1234Next »
    Content Partners